https://www.cnbc.com/2024/02/29/pfizer-rsv-vaccine-protects-older-adults-over-two-seasons.html
Feb 29, 2024 - The results come ahead of a meeting of an advisory panel to the CDC, which will consider whether seniors should take RSV shots annually or every other year.
0
cnbc:-473801050523543498
0
https://seekingalpha.com/news/4075698-guggenheim-upgrades-gsk-to-buy-from-neutral?source=feed_sector_healthcare
Mar 04, 2024 - Guggenheim upgrades GSK (GSK) stock to buy, citing higher revenue estimates, improving margins, and potential resolution of the Zantac overhang. Read more here.
0
sa:902701321099366028
0
https://seekingalpha.com/news/4075584-sen-warren-accuses-gsk-of-price-gouging-over-pediatric-asthma-drug?source=feed_sector_healthcare
Mar 04, 2024 - U.S. Sen. Elizabeth Warren has slammed GSK (GSK) for alleged price-gouging over the marketing of its pediatric asthma drug Flovent HFA and its authorized generic. Read more here.
0
sa:3161199320136769391
0
https://www.zacks.com/stock/news/2196699/gsk-s-jemperli-gets-eu-nod-for-endometrial-cancer-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2196699
Dec 12, 2023 - GSK's Jemperli combo receives the European Commission's marketing authorization as a frontline treatment for certain types of primary advanced/recurrent endometrial cancer.
zc:-8265856814027053476
0
https://www.zacks.com/stock/news/2200785/gsk-gsk-stock-moves-0-85-what-you-should-know?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2200785
Dec 20, 2023 - The latest trading day saw GSK (GSK) settling at $36.19, representing a -0.85% change from its previous close.
zc:-2388076021329619211
0
https://www.zacks.com/stock/news/2201156/merck-s-mrk-chronic-cough-drug-gets-another-crl-from-fda?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201156
Dec 21, 2023 - Per the FDA, the data submitted by Merck (MRK) for its chronic cough drug did not provide sufficient evidence to prove its clinical benefit in patients.
zc:6239401725016099411
0
https://www.zacks.com/stock/news/2201105/gsk-hansoh-ink-deal-to-develop-lung-cancer-adc-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2201105
Dec 21, 2023 - GSK enters into an exclusive licensing agreement with China-based Hansoh to develop and commercialize the latter's lung cancer candidate, HS-20093.
zc:1648271226051285024
0
https://www.zacks.com/stock/news/2204687/gsk-gsk-rises-as-market-takes-a-dip-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v2-2204687
Jan 02, 2024 - GSK (GSK) concluded the recent trading session at $37.51, signifying a +1.21% move from its prior day's close.
zc:-100405180713501274
0
https://www.zacks.com/stock/news/2206174/these-2-medical-stocks-could-beat-earnings-why-they-should-be-on-your-radar?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_earnings_esp-2206174
Jan 05, 2024 - The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
zc:-452165552183118082
0
https://www.zacks.com/stock/news/2206453/why-glaxo-gsk-is-poised-to-beat-earnings-estimates-again?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_7-2206453
Jan 05, 2024 - Glaxo (GSK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
zc:-6854388715619854829
0